KPV and GHK-Cu as a 'beauty blend': what the science says

What did @dereklifts2 actually say?

The creator argues that a GHK-Cu plus KPV combination is a smarter skin-focused choice than blends like "glow" or "klow" because those products mix in BPC-157 and TB-500, which he says you should "reserve for injury." He credits GHK-Cu with collagen synthesis and skin remodeling, and KPV with calming inflammation, calling it useful for eczema and other skin conditions. He also directs viewers to a price comparison tool to find the cheapest vendor. That last part is the piece that deserves the most scrutiny before anything else. Comparing vendor prices for unregulated research peptides is not a neutral consumer service. It is a purchasing funnel, and that context matters when evaluating how the health claims are framed throughout.

To his credit, the creator is not inventing these peptides or their proposed mechanisms. Both GHK-Cu and KPV have actual research behind them, even if the human trial data is thin. The framing here is more measured than the typical TikTok peptide content, but "more measured" is not the same as scientifically sound.

Does the science back this up?

GHK-Cu has the stronger evidence base of the two. KPV has real data, mostly in preclinical models, but the leap to human skin benefits is not established. GHK-Cu's collagen-related activity is documented in cell and animal studies, but large randomized controlled trials in humans are still absent.

GHK-Cu (copper tripeptide-1) has been studied since the 1970s. Pickart and Margolina (2018, Cosmetics) summarized decades of work showing GHK-Cu stimulates collagen and elastin synthesis and acts as an antioxidant in cell models. Leyden et al. (2018, Journal of Cosmetic Dermatology) found improvements in fine lines in a small randomized trial using a topical GHK-Cu formulation. The mechanism is plausible. The human evidence is limited but not zero.

KPV (lysine-proline-valine) is a C-terminal fragment of alpha-MSH. Most of its anti-inflammatory data comes from rodent models of inflammatory bowel disease and wound healing, not human skin. Dalmasso et al. (2008, Peptides) showed KPV reduced colitis markers in mice. Translating that to eczema or skin inflammation in people is a significant jump that the creator makes without flagging the evidence gap.

What did they get wrong (or right)?

The reasoning for separating BPC-157 and TB-500 from a skin blend is actually defensible. The creator is wrong to imply KPV is well-established for eczema, but right that stacking injury-recovery peptides into a cosmetic blend adds cost and complexity without a clear rationale for skin-only goals.

Where the creator goes wrong: saying KPV "will do more than enough to calm any of that inflammation" and calling it "great for people with eczema" treats preclinical data as clinical evidence. There are no published human trials showing KPV injections or topical KPV improve eczema outcomes. Making that claim to 5,700 viewers, many of whom may have active skin conditions, is irresponsible without that caveat.

Where he gets it right: the logic of not combining peptides with different therapeutic targets into a single blend is sound from a pharmacology standpoint. If your goal is skin, adding systemic healing peptides like TB-500 does not obviously help and does add cost. That reasoning holds up.

The vendor price comparison framing is a conflict of interest that goes undisclosed. Viewers should know that before taking any purchasing advice from this content.

What should you actually know?

Neither GHK-Cu nor KPV has FDA approval for any skin condition. Purchasing injectable peptide blends from online vendors to treat eczema or any skin disorder carries real risks that this video does not address at all.

Injectable peptides sourced from unregulated vendors are not subject to the sterility, potency, or purity testing required of pharmaceutical-grade compounds. The FDA has issued warnings about compounded peptides, and several research chemical suppliers have faced enforcement actions. If you are interested in GHK-Cu for skin, there are topical formulations available through licensed dermatology channels that have at least some human safety data behind them.

For anyone with a genuine skin condition like eczema, the standard of care involves dermatologist-evaluated treatments with actual clinical trial data. Biologics like dupilumab have large Phase 3 trial packages behind them. KPV does not. That gap matters. A TikTok video comparing vendor prices is not a substitute for a clinical evaluation, regardless of how plausible the underlying peptide science sounds.